Scarica l'app Stockscreener
0.6185
10.75%
-0.0745
Precedente Chiudi:
$0.693
Aprire:
$0.6997
Volume 24 ore:
1.07M
Relative Volume:
0.77
Capitalizzazione di mercato:
$43.98M
Reddito:
$391.70K
Utile/perdita netta:
$-52.34M
Rapporto P/E:
-0.8247
EPS:
-0.75
Flusso di cassa netto:
$-45.92M
1 W Prestazione:
+12.45%
1M Prestazione:
+96.66%
6M Prestazione:
-15.75%
1 anno Prestazione:
-41.65%
Intervallo 1D:
$0.6097
$0.6999
Intervallo di 1 settimana:
$0.56
$0.7331
Portata 52W:
$0.2425
$1.47
Ovid Therapeutics Inc Stock (OVID) Company Profile
Nome
Ovid Therapeutics Inc
Settore
Industria
Telefono
212-776-4381
Indirizzo
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Confronta OVID con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
0.6185 | 49.28M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-18 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-04-30 | Iniziato | B. Riley Securities | Buy |
| 2024-04-29 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-05 | Iniziato | Wedbush | Outperform |
| 2023-12-21 | Iniziato | BTIG Research | Buy |
| 2023-10-13 | Iniziato | Oppenheimer | Outperform |
| 2021-04-20 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-04-20 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Ovid Therapeutics Inc Borsa (OVID) Ultime notizie
Ovid Therapeutics Inc. Stock Analysis and ForecastFree Market Dynamics Reports - PrintWeekIndia
Ovid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica Pharma - MSN
What drives Ovid Therapeutics Inc. stock priceConsistently profitable trades - PrintWeekIndia
Why Ovid Therapeutics Inc. stock attracts strong analyst attentionFree Real-Time Market Predictions - Newser
Is Ovid Therapeutics Inc. a good long term investmentLightning-fast capital gains - Autocar Professional
Ovid Therapeutics shares rise 4.29% premarket after announcing participation in the BTIG Virtual Biotechnology Conference. - AInvest
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference - GlobeNewswire
12 Best Penny Stocks Under $1 to Buy Now - Insider Monkey
What analysts say about Ovid Therapeutics Inc. stockBreakout profit opportunities - Autocar Professional
Ovid Therapeutics' Strategic Position in the Seizure and CNS Disorder Market: Pipeline Innovation and Partnership Potential - AInvest
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference | OVID Stock News - GuruFocus
Brain Medicine Developer Ovid Therapeutics Reveals Latest Progress at Major BTIG Biotech Conference - Stock Titan
July 2025's Top Penny Stocks To Watch - simplywall.st
Ovid Therapeutics Stock Soars 13.88% on Investor Optimism - AInvest
Ovid Therapeutics (NASDAQ:OVID) Receives Average Rating of “Buy” from Analysts - Defense World
Ovid Therapeutics (NASDAQ:OVID) Stock Rating Upgraded by Wall Street Zen - Defense World
What makes Ovid Therapeutics Inc. stock price move sharplyFree Access to Community with 300% Return - beatles.ru
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Ovid Therapeutics Surges 25% Amid Analyst Hype and Strategic Pipeline Progress - AInvest
Oliveda International, Inc. (OLVI) Announces Over 70% Growth in the First Half of 2025 - Yahoo.co
How Ovid Therapeutics Inc. stock performs during market volatilityTop Rated Trade Entries - Newser
Ovid Therapeutics (NASDAQ:OVID) Stock Price Down 2% – Time to Sell? - Defense World
Ovid Therapeutics Approves Key Proposals at Annual Meeting - The Globe and Mail
Local Bounti (LOCL) insider files Form 144 to sell 3,500 shares - Stock Titan
Ovid Therapeutics Sells Ganaxolone Royalties to Immedica - TipRanks
Ovid Therapeutics Inc Azioni (OVID) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):